Versea will have exclusive commercial rights to Axim’s lab testing and diagnostic tests for dry eye and allergic conjunctivitis, as well as any tests set to launch in the next 18 to 24 months, according to a Sept. 19 news release from Axim.
Versea also recently appointed Rob Sambursky, MD, as its president of corporate and Versea Ophthalmolics in an effort to expand its reach in the ophthalmology space.
“With exclusive global licensing rights to Axim’s Eye Diagnostics portfolio, Versea will be introducing a new innovative, rapid, tear-based, POC lab-testing platform designed specifically to assist eye-care clinicians in detecting and quantifying a variety of biomarkers associated with external ocular disorders,” Sean Fetcho, CEO and co-founder of Versea, said in the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.